Machine learning and Mendelian randomization prioritize CA2 as a diabetic nephropathy biomarker
Across six kidney-expression datasets, researchers identified 314 differentially expressed genes in diabetic nephropathy and used LASSO, SVM-RFE and random forest to prioritize seven candidate genes. Mendelian-randomization integration further prioritized carbonic anhydrase II (CA2); its ROC AUC exceeded 0.878 across the analyzed datasets. The authors also reported qPCR validation of CA2 in clinical patient and control samples and an association with inferred immune-cell infiltration.
Technology: LASSO, support-vector-machine recursive feature elimination and random-forest feature selection
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors also reported qPCR validation of CA2 in clinical patient and control samples and an association with inferred immune-cell infiltration.
- Still unknown: This is a candidate biomarker study, not evidence of a clinically deployed test or patient benefit. Reported AUC values are retrospective dataset performance; qPCR validation supports differential expression but does not establish CA2 as causal or disease-specific. The accessible abstract does not report the clinical validation sample size, so none is inferred.
- AI role: Three machine-learning approaches integrated candidate-gene selection from kidney-expression datasets; Mendelian randomization with expression-QTL data then prioritized CA2, which was evaluated as a diagnostic biomarker and measured by qPCR in clinical samples. The models supported gene prioritization and discrimination, while qPCR supplied the wet-lab follow-up.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39370621/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.